从烟台市市场监管局获悉，为抢抓产业高质量发展战略机遇，加快构建现代化医疗器械产业体系，烟台 市立足"1+3+X"生物医药产业总体布局，制定出台《烟台市医疗器械产业发展规划(2025—2029年)》(以 下简称《规划》)，明确未来五年产业发展的目标路径、空间布局、攻坚任务与保障措施，全力打造具 有国际竞争力的医疗器械创新高地与产业集群。 在产业生态培育上，新引进2—3家具备核心研发能力的医疗器械企业在烟设立总部或研发生产基地，同 步培育一批专精特新、单项冠军、瞪羚企业；依托烟台各区市特色优势，高标准建成1个核心产业园 区，打造3—5个特色产业基地，形成覆盖产品研发、生产、流通、医疗服务的产业垂直生态体系。 齐鲁晚报.齐鲁壹点秦雪丽通讯员孙洪安 剑指百亿规模 构建高能级产业生态 《规划》锚定"集群联动、创新驱动、生态融合、国际竞合"核心目标，提出到2029年，全市医疗器械产 业总体规模力争突破100亿元，其中高附加值医疗器械占比达到40%以上，实现产业规模与发展质量双 提升。 四区联动聚合力。芝罘区、莱山区、牟平区、黄渤海新区四区联动，重点布局涉氧器械、康复辅具、医 学影像设备、血液诊断、类器官芯片、生物再生材料 ...

Summary of the Conference Call for 康龙化成 (Crown Bioscience) Q1 2025 Company Overview - 康龙化成 reported a revenue of 30.96 billion CNY in Q1 2025, representing a year-on-year growth of 15.4% [2][3] - The company maintains its revenue growth guidance for 2025 at 10% to 15% and expects to continue generating positive free cash flow [2][9] Key Financial Performance - The adjusted net profit for Q1 2025 was 3.49 billion CNY, a year-on-year increase of 3.1%, while the net profit attributable to shareholders was 3.06 billion CNY, up 32.5% [3][4] - The laboratory services segment generated 18.57 billion CNY, with a gross margin of 45.5%, up 1.4 percentage points [2][5] - The small molecule CDMO services segment reported revenue of 6.93 billion CNY, with a gross margin of 30.4%, an increase of 2.5 percentage points [2][5] - Clinical services revenue was 4.47 billion CNY, with a gross margin of 11.8%, up 2.5 percentage points [2][5] - The revenue from large molecule and cell & gene therapy services was 99 million CNY, showing a year-on-year growth of 7.9% [2][5] Revenue Breakdown by Region and Client Type - Revenue from Chinese laboratories and factories grew by 15.7%, accounting for 88% of total revenue; overseas revenue increased by 18.3%, making up 12% [2][6] - North American client revenue rose by 16.8%, representing 65% of total revenue; European client revenue increased by 26%, accounting for 18% [2][6] Order Growth and Market Trends - New orders maintained a double-digit growth of over 10% in Q1 2025, continuing the trend from the previous year [2][7] - The CMC business is focused on early clinical stages, with expectations for several large projects to advance into later stages, which will enhance CMC revenue and overall performance [4][23] Strategic Initiatives and Future Outlook - The company is investing in advanced technologies in the biosciences field, including 3D cell culture and organ-on-a-chip models, to stay at the forefront of industry developments [4][12] - The company anticipates that the adjusted net profit growth will accelerate from Q2 2025 onwards as operational efficiencies improve [3][4] - The overall market for laboratory services and biosciences is expected to continue its recovery, with double-digit growth anticipated in both sectors [9][20] Challenges and Considerations - The company faces challenges related to increased operational costs and depreciation due to new capacity coming online in 2024 [4][3] - The impact of geopolitical factors, such as tariffs and the IRA Act, on client R&D and production needs is being monitored, but the company remains optimistic about its growth trajectory [14][19] Conclusion - 康龙化成's Q1 2025 performance reflects strong growth across its segments, with a positive outlook for the remainder of the year, driven by strategic investments and a robust order pipeline [29]